Ban on generic drug patent deals

Summary#

The Protecting Consumer Access to Generic Drugs Act of 2026 would create a new federal prohibition and amend the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Federal Food, Drug, and Cosmetic Act, and the Federal Trade Commission Act. Its stated goal is to prevent agreements that pay or otherwise benefit generic or biosimilar makers for delaying a product’s entry into the market.

  • It would make it unlawful for a brand-name drug or biologic company—or one later-filing drug company and another—to give a later filer something of value in a patent-settlement agreement in exchange for limiting or giving up work on the product.
  • The ban would cover limits on research, development, manufacturing, marketing, or sales. It would apply to agreements made on or after the Act becomes law.
  • The bill allows certain settlement terms, including an earlier right to market, reasonable legal-cost payments of up to $7.5 million total, and a promise not to sue over patent infringement. It also provides an exception for value shown by clear and convincing evidence to be solely payment for other promised goods or services.
  • The Federal Trade Commission (FTC) would enforce the ban. It could seek civil penalties, injunctions, and other relief; a court-set penalty would be capped at up to three times specified value connected to the violation.
  • It would add a certification requirement for company leaders responsible for certain filed agreements and make a violation a ground for losing a generic drug’s 180-day exclusivity period (a period of exclusive sales).

What it means for you#

  • People who use medicines: The bill is intended to address deals that can delay generic or biosimilar competition. It does not guarantee that a particular product will enter sooner, cost less, or become available.
  • Brand-name drug and biologic companies, and generic or biosimilar applicants: They could not make or carry out covered agreements that exchange something of value for limits on the later filer’s work on the product, unless an exception applies.
  • Companies required to file certain agreements: The responsible chief executive or negotiating official would have to certify within 30 days that the filed materials are complete and include specified related agreements and descriptions of relevant oral promises.
  • FTC: It would gain express enforcement authority under this bill. The FTC may also exempt certain agreements by rule if it finds they promote competition and benefit consumers.
  • The bill does not directly change medicine prices, create a new patient benefit, or ban patent settlements generally.

Money#

No cost information is in the available material.

  • The bill authorizes the FTC to pursue enforcement, penalties, and court orders, but provides no estimate of staffing or enforcement costs.
  • It does not set a new tax or fee. It permits reasonable litigation-expense payments of up to $7.5 million in the specified settlements.

What is unclear#

  • The bill does not define some key terms, including “anything of value” and how much value is “reasonably attributable” to a violation.
  • It does not set out a new process for reviewing agreements before they are made; enforcement would depend on the FTC’s use of its authority.
  • The text does not explain how the new agreement certification would work alongside existing filing procedures in every case.
  • The bill is not law. It was referred to House committees, and whether it will pass is uncertain.
  • No publicly available information.

Case for#

  • A possible argument for the bill is that a company should not be able to pay a potential competitor to delay work on a competing medicine.
  • The prohibition covers both generic drugs and biosimilar products, and includes limits on research and development as well as sales.
  • Requiring senior officials to certify that filings include related agreements and oral promises could help identify arrangements that are not fully described in the main written agreement.
  • FTC enforcement and penalties could discourage covered deals, while the listed settlement exceptions preserve some ways to resolve patent disputes.

Case against#

  • One concern is that “anything of value” and agreements “otherwise related” to a patent settlement may leave companies uncertain about which settlement terms are prohibited.
  • The bill permits some payments and settlement terms, but disputes could arise over whether a payment is solely for other services or whether a deal fits an exception.
  • The FTC could seek significant penalties, while the bill does not specify how courts should measure value “reasonably attributable” to a violation beyond listing factors to consider.
  • The bill does not estimate the cost of added certification or enforcement work.